CLINICAL DATA

Case Report

Dalal et al (2021)¹ reported the case of a 27-year-old female with pan-ulcerative colitis (UC) after primary nonresponse to infliximab and vedolizumab.

• The patient presented with complaints of diarrhea, hematochezia, and abdominal cramps for several weeks.
• She was initially treated with 5-aminosalicylic acid (5-ASA) and azathioprine, which did not control her symptoms.
• She was switched to infliximab 5 mg/kg every 8 weeks (q8w). However, after several months of treatment, a colonoscopy revealed persistent, moderate proctitis. Despite an infliximab dose escalation, the patient had moderate inflammation in the intestines as seen on follow-up colonoscopies.
• The patient was subsequently treated with vedolizumab, oral budesonide, and azathioprine due to persistent symptoms. After 3 months of combination therapy with azathioprine and vedolizumab, a colonoscopy revealed mild proctitis and moderate inflammation in the intestines.
• She transitioned to a partial elemental diet, which did not improve her symptoms or mucosal inflammation.
• STELARA therapy was initiated on a standard weight-based infusion followed by subcutaneous (SC) maintenance dosing q8w. After 3 months of treatment, the patient achieved clinical remission.
  • After 12 months of maintenance therapy, colonoscopy findings were consistent with endoscopic remission (no mucosal inflammation, except for erythema and granularity in 2 small patches in the right colon).
  • At 22 months of follow-up, the patient continued to be in clinical remission while receiving maintenance therapy of STELARA SC q8w.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 22 July 2024.